Takeda Pharma, H Lundbeck start MDD drug Phase III trial
In the trial, the companies will investigate the safety of Lu AA21004 (5 and 10 mg) compared to placebo. The primary endpoint of the Phase III trial is
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.